Antitumor reactivity of T cells transduced with CTE-engineered γ9δ2TCRs in vivo. The functional avidity of T cells expressing CTE-γ9δ2TCR γ9-G115_wt/δ2-cl5_wt or control γ9δ2TCR (γ9-G115_wt/δ2-G115_wt) was studied in Rag2^−/−γc^−/− double-knockout mice (4-7 mice per group). After total body irradiation (2 Gy) on day 0, mice were IV injected with 0.5 × 10⁶ Daudi-luciferase or 5 × 10⁶ RPMI8226/S-luciferase cells and 10⁷ CTE-γ9δ2TCR–transduced T cells at day 1. In addition, 6 × 10⁵ IU of IL-2 in IFA and pamidronate (10 mg/kg body weight) were injected at day 1 and every 3 weeks until the end of the experiment. (A-B) Tumor outgrowth was assessed in vivo by bioluminescence imaging measuring the entire area of mice on both sides. Data represent the means of all animals measured (Daudi, n = 4; RPMI8226/S, n = 7). *P < .05; and **P < .01 by 1-way ANOVA (Daudi at day 42 and RPMI8226/S at day 35). (C) Overall survival of treated Daudi mice was monitored for 72 days. *P < .05; and **P < .01 by log-rank (Mantel-Cox) test.